Skip Navigation



European Heart Journal Advance Access published online on July 26, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl152
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/18/2158    most recent
ehl152v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hilbrich, L.
Right arrow Articles by Sleight, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilbrich, L.
Right arrow Articles by Sleight, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2006; all rights reserved
Received January 31, 2006
Revised May 29, 2006
Accepted June 29, 2006

Review

Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials

Lutz Hilbrich 1 * and Peter Sleight 2

1 Medical Science Department, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim, Germany
2 Department of Cardiovascular Medicine, Level 5, John Radcliffe Hospital, Oxford, UK

* To whom correspondence should be addressed.
Lutz Hilbrich, E-mail: hilbrich{at}ing.boehringer-ingelheim.com or lhilbrich@rdg.boehringer-ingelheim.com


  Abstract

Randomized clinical trials (RCTs) are the definitive contributors to evidence-based medicine. RCTs assessing serious outcomes in cardiovascular disease have grown, with ‘megatrials’ becoming more common with the realization that wrong conclusions resulted from random error in inadequately sized trials. Simple design and a heterogeneous patient population were early features, but multinational trials have increased in scientific, logistical, bureaucratic, regulatory, and legal complexity. These studies now exceed the financial means of academia or medical charities. Governments have left the bill with the pharmaceutical industry, encouraging a symbiosis with academics, who contribute medical and scientific expertise, and access to patients. Industry provides pharmacological, pharmaceutical, technical and regulatory know-how, good clinical practice expertise, and legal assistance during the trial. Study supervision is then in the hands of an independent steering committee and associated subcommittees, until appropriate dissemination of results. Prospectively defined interaction with the sponsor facilitates unbiased design and conduct, but arrangements need careful implementation to avoid conflicts of interest. The patient is protected by a strong data safety monitoring board that is wholly independent. Megatrials are under threat from over-regulation, increasing costs, and difficulties in execution. These issues merit urgent public and political education and debate.

Keywords: Cardiovascular disease; Randomized clinical trials; Industry collaboration; Funding; Ethics; Regulation; Conflicts of interest.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JBJSHome page
D. J. Hoppe, E. H. Schemitsch, S. Morshed, P. Tornetta III, and M. Bhandari
Hierarchy of Evidence: Where Observational Studies Fit in and Why We Need Them
J. Bone Joint Surg. Am., May 1, 2009; 91(Supplement_3): 2 - 9.
[Abstract] [Full Text] [PDF]

Home page
 AJPHHome page
G. Bukhman and A. Kidder
Cardiovascular Disease and Global Health Equity: Lessons From Tuberculosis Control Then and Now
Am J Public Health, January 1, 2008; 98(1): 44 - 54.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.